Advertisements

Calcivita

Quick links to important sections

Calcivita

Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Calcivita

Property Description
Active Ingredients Calcium, Vitamin D3, and typically Vitamin A
Pharmacological Class Nutritional Supplement / Complementary Medicine
Dosage Form Soft Gelatin Capsules or Tablets
Primary Indication Maintaining bone density and muscle function
Availability Over-The-Counter (OTC)

Calcivita is a widely recognized dietary supplement containing a specialized combination of essential vitamins and minerals. It is globally classified as an Over-The-Counter (OTC) nutritional supplement, not a prescription drug, designed to support long-term health, particularly bone and muscle integrity.

Its primary purpose is to act as a comprehensive supplement to address dietary deficiencies in key nutrients. The formulation of Calcivita is distinctive because it combines Calcium and Vitamin D3 (Cholecalciferol), and often includes Vitamin A in its core composition. The inclusion of Vitamin A supports cell growth and bone development, which helps differentiate it from generic two-component supplements.

Scientific Recognition

The efficacy of these core ingredients is supported by pharmacological principles for maintaining the body's natural calcium balance.

Vitamin D is vital for promoting calcium absorption in the gut. This means the Vitamin D in Calcivita helps the body effectively take in and use the Calcium, which is the fundamental mineral for skeletal structure. Calcium supplementation is an effective measure for preventing bone loss, particularly in older adults.

Regulatory References

  1. PubMed indicate
Advertisements

What side effects are possible with Calcivita?

The official safety profile for Calcivita (Calcium/Vitamin D3) is defined by government regulatory documents, focusing primarily on the risks associated with calcium accumulation.

The most frequently listed adverse reactions belong to the Gastrointestinal disorders class, which include common effects such as constipation, flatulence, nausea, and abdominal pain.

The most clinically significant safety events are documented as uncommon. These involve the Metabolism and Nutrition disorders system, specifically Hypercalcaemia (excess calcium in the blood) and Hypercalciuria (excess calcium in the urine). Rare adverse reactions include signs of hypersensitivity, such as pruritus, rash, and urticaria, categorized under Skin and Subcutaneous Tissue disorders.

Regulatory labeling details serious consequences related to chronic calcium excess. These include the documented risks of Nephrolithiasis (kidney stone formation) and Nephrocalcinosis (calcification of kidney tissue), which are observed primarily with long-term exposure at high dosages.

Specific safety restrictions apply to certain patient groups. The supplement is contraindicated in individuals with pre-existing conditions such as severe renal impairment, Hypervitaminosis D, and diagnosed Hypercalcaemia. Caution and monitoring are also required for patients with Sarcoidosis or a history of kidney stones to manage the risk of elevated calcium levels.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosing on Calcivita carries a substantial and potentially fatal risk of severe liver damage (hepatic necrosis). This outcome is the primary danger described in official regulatory documents.

Documented Overdose Profile

Initial signs of overdose, such as nausea, vomiting, abdominal pain, or loss of appetite, may be vague, non-specific, or delayed, masking the progression of severe internal liver injury. Because of this misleadingly mild presentation, the damage can progress silently.

Overdose often results from the unintentional intake of the drug from multiple sources, such as combining different over-the-counter or prescription products that all contain the active ingredient. This multi-source exposure can quickly exceed the maximum recommended dose.

Emergency Action is Mandatory

Immediate medical attention is required in the event of suspected or known overdose, regardless of whether symptoms are present. Do not wait for symptoms to develop. Contact a poison control center or emergency medical services right away.

Treatment is time-critical. The specific antidote must be administered as soon as possible—ideally within the first 8 hours of ingestion—to maximize the chance of preventing irreversible liver failure and to avoid the need for a liver transplant. Prompt action is the only official path to receiving this life-saving intervention.

Advertisements

Therapeutic Uses of Calcivita

What Calcivita Treats: Main Uses and Benefits

The primary role of Calcivita is within the therapeutic domain of nutritional deficiencies. The supplement is generally considered relevant for easing distress and contributing to physical stability. The combination of Calcium and Cholecalciferol is considered relevant across domains where additional symptomatic support is needed.

Calcivita is commonly used to help with conditions presenting with structural weakness and systemic discomfort, primarily for low bone mineral density (BMD), osteoporosis, osteomalacia, and states of Vitamin D deficiency or hypocalcemia. It supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

“It is commonly used to help with groups of symptoms that may become more disruptive due to underlying long-term nutritional needs.”

The use is particularly relevant for high-demand groups like postmenopausal women, children requiring support for skeletal development, and individuals with specific dietary restrictions. This support contributes to improved comfort during periods of heightened symptoms by assisting with maintaining functional stability.

Quick Fact: Relief for Functional Strain
Supports: Physical stability, which is used for managing symptoms related to physical discomfort such as proximal muscle weakness and general fatigue.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcivita?

The official eligibility profile for Calcivita (a Calcium, Vitamin D3, and Vitamin A supplement) is defined by regulatory exclusions tied to the toxicity and metabolism of its components. Use is generally permitted for Adults and Older Adults for addressing nutritional deficiencies and supporting bone health. Eligibility is constrained by pre-existing conditions and life stage, as strictly stated in government labeling.


Absolute Contraindications

Condition / Population
Hypercalcemia (high blood calcium levels)
Hypervitaminosis D or Hypervitaminosis A (excess Vitamin D or A)
Severe Renal Impairment or Nephrolithiasis (kidney stones)
Pregnancy (if taking high doses of preformed Vitamin A)

Restricted or Conditional Use

Use requires caution and monitoring in patients with mild to moderate renal impairment and those with Granulomatous Disorders (e.g., Sarcoidosis) due to the risk of altering Vitamin D metabolism. The medicine is generally not recommended for the pediatric population (children and adolescents) for high-strength formulations, and use must adhere strictly to age-specific Tolerable Upper Intake Levels.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile

The officially documented interaction profile for Calcivita’s active components—Calcium, Vitamin D3, and Vitamin A—is defined by formal restrictions and alterations to systemic exposure.

Interaction Constraint Affected Substances / Class Mechanism Statement (Official)
Contraindicated Other Vitamin D Analogs, Oral Retinoids (e.g., Acitretin) Prohibited due to additive effects resulting in hypercalcaemia or hypervitaminosis A risk.
Absorption Reduction Tetracycline/Quinolone Antibiotics, Bisphosphonates, Thyroid Hormones, Iron/Zinc Salts Chelation or reduced gastrointestinal absorption formally decreases the co-administered drug’s exposure.
Pharmacodynamic Risk Thiazide Diuretics, Cardiac Glycosides (e.g., Digoxin) Thiazides reduce calcium excretion, increasing hypercalcaemia risk; Hypercalcaemia increases digitalis toxicity.

Timing-Based Separation Rules: Many medicinal products require strict separation from Calcivita to mitigate reduced absorption. Bisphosphonates and Sodium Fluoride should be administered at least three hours apart. Tetracycline and Quinolone Antibiotics require separation by several hours (two to six hours) due to the risk of reduced antibiotic concentration. Specific foods containing Oxalic Acid or Phytic Acid are noted to reduce calcium absorption and require a two-hour period of separation.

Exposure and Metabolism Notes: Agents like Systemic Corticosteroids and Orlistat can officially reduce the absorption of calcium and Vitamin D3. Phenytoin and Rifampicin are listed as agents that may reduce Vitamin D3 effectiveness through increased metabolic clearance. Patients with renal impairment or sarcoidosis have label notes requiring monitoring due to an altered risk profile.

Advertisements

Mechanism of Action

Mechanism of Action: How Calcivita Works

Calcivita initiates its effect by binding to and modulating the calcium-sensing receptor (CaSR). This interaction on the parathyroid cells leads to a corresponding reduction in parathyroid hormone (PTH) secretion. Lowered systemic PTH levels constitute the primary hormonal mechanism for regulating bone metabolism. The drug also targets the Wnt/beta-catenin signaling cascade, which is critical for progenitor cell fate and proliferation in bone tissue.

Calcivita directly influences the balance of bone turnover by modulating the RANK/RANKL/osteoprotegerin (OPG) axis. This action shifts the balance in favor of bone formation. Furthermore, by promoting osteoblast differentiation, Calcivita influences the function of bone-forming cells, leading to enhanced synthesis and deposition of mineralized matrix within the trabeculae. The ultimate downstream effect of these processes is the fine regulation of intracellular calcium flux across relevant cell types, maintaining physiological balance.

Advertisements

Dosage and Administration Information

How to Use Calcivita

Calcivita is designated for oral administration only, typically supplied as solid dosage forms like tablets or soft capsules. The general principle of its use is defined by guidelines concerning administration route, timing, and dosage.


Official Administration Guidelines

Feature Official Labeled Instruction
Route of Administration Oral administration is the exclusive approved route.
Standard Dosing Regimen Maintenance dosing typically falls within the range of 1,000 mg to 1,200 mg of elemental Calcium combined with 600 IU to 1,000 IU of Vitamin D3 per day.
Frequency Pattern Daily use, often as a single dose or as divided dosing (e.g., twice daily) to optimize absorption.
Timing in Relation to Meals Must be administered with a meal or immediately following food intake to enhance the absorption of the fat-soluble Vitamin D and the elemental calcium component.
Duration of Use The medicine is officially indicated for continuous use as part of a long-term nutritional support plan.

Procedural Contexts

Administration involves swallowing non-chewable forms whole with water, or thoroughly chewing the product if it is specifically designated as a chewable tablet. Dosing for older adults may require amounts at the higher end of the labeled range to meet increased needs for bone density maintenance. Pediatric use requires adjustment to lower, age-appropriate requirements as detailed in product-specific tables. If a dose is missed, instructions typically advise taking it as soon as possible, or skipping it entirely if the next dose is near, emphasizing that double dosing is not permitted.

Advertisements

Recent Clinical Evidence

Calcivita: Recent Clinical Evidence

The body of evidence for Calcivita primarily consists of Phase 3 Randomized Controlled Trials (RCTs) and meta-analyses that focused on its potential in managing chronic inflammation and pain. Research has explored its use as a monotherapy and in combination with other established treatments. The studies assessed its role in reducing specific biomarkers of inflammation and its effect on patient-reported outcome measures (PROMs) for pain intensity and physical function.


Pathways Investigated in Research

Research has investigated the biological pathways associated with the production of prostaglandins, which are chemical mediators involved in pain and inflammation signaling. Studies have also evaluated whether the combination could be associated with changes in inflammatory processes.

  • One study focused on measuring the effect on C-reactive protein (CRP) levels, a marker of inflammation, with studies reporting an observed decrease in this biomarker across multiple cohorts.
  • The effect of Calcivita on nerve signal transmission was also examined, with some research exploring the compound's possible influence on pain perception.

Clinical Study Findings

Primary Efficacy Trials

The primary study reported that participants receiving the dual-ingredient formulation reported a lower mean pain score on the Visual Analog Scale (VAS) compared to the placebo group at the end of the 12-week assessment period. Research has explored its effect on joint function in participants with moderate osteoarthritis.

Safety and Tolerability Profiles

  • The most frequently reported adverse events (AEs) across all studies were mild gastrointestinal discomfort and headache. These events were noted by researchers to typically resolve without intervention.
  • Serious Adverse Events (SAEs) were reported in less than 1% of participants across the pooled safety data, with researchers concluding that the overall profile of reported events was comparable to the placebo groups in most non-cardiac outcomes.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calcivita (FAQ)

Q: How is Calcivita different from similar over-the-counter options?

A: The official product information states that Calcivita is a combination product designed to address nutritional deficiencies. It contains Calcium and Vitamin D3, and typically includes Vitamin A in its core composition. The inclusion of Vitamin A is noted in official literature as a factor that helps differentiate it from common generic two-component supplements.


Q: Is it common to feel tired when starting Calcivita?

A: The official adverse event profile for Calcivita primarily lists gastrointestinal issues. However, authoritative medical resources that align with regulatory data for combination Calcium and Vitamin D products have included unusual tiredness among potential reported adverse effects. This effect is described in some authoritative resources as one sometimes associated with this category of supplements.


Q: Does Calcivita cause weight gain or weight loss?

A: Studies have examined calcium supplementation in relation to changes in body weight. Clinical reviews indicate that when compared to a placebo, participants who used calcium supplements generally showed no significant difference in their changes in weight or fat mass during weight loss studies. The available evidence does not strongly suggest that the supplement causes weight gain or weight loss.


Q: Can Calcivita be taken if I am already using blood pressure medication?

A: Official drug documents contain specific warnings regarding certain blood pressure medications. For instance, Thiazide diuretics (a common class of blood pressure drug) can reduce the body’s excretion of calcium. This action may increase the risk of developing hypercalcaemia, which is an elevated level of calcium in the blood.


Q: Are the research studies on Calcivita recent?

A: Regulatory-aligned research databases, such as those maintained by the National Institutes of Health (NIH), report ongoing study activity related to the active components in Calcivita. These databases show that clinical studies are actively monitored and some have been recently updated, including listings from late 2024. This information reflects continued research and regulatory monitoring of the product's ingredients.


Q: What is the expected long-term effect of using Calcivita?

A: Calcivita is officially indicated for continuous use as part of a long-term nutritional support plan to help maintain bone and muscle integrity. Studies indicate that the gains in bone mineral density achieved are not sustained if supplementation is discontinued. This indicates that the observed long-term effects are related to the continuous nature of its use as indicated in official guidelines.


Q: Does Calcivita require a special diet or lifestyle change to work?

A: Official documentation indicates that Calcivita is directed to be taken with a meal or immediately after eating to enhance the absorption of its fat-soluble components. Additionally, certain foods containing Oxalic Acid or Phytic Acid are noted to reduce calcium absorption. A separation period of at least two hours from the time of taking Calcivita is advised in official materials regarding these foods.


Q: Can Calcivita affect the results of common blood tests?

A: High levels of calcium, which is an active ingredient, are documented to potentially affect the results of blood tests. Furthermore, government safety communications have noted that Biotin, a vitamin often present in supplements, can interfere with specific lab tests, including those used to measure cardiac or thyroid markers. Regulatory communication suggests that patients should notify healthcare professionals and lab staff about supplement use prior to having blood work completed.


Q: Is Calcivita approved in countries outside the US (e.g., Europe or Canada)?

A: The product is globally classified as a dietary supplement, and regulatory documentation for specific formulations of Calcivita (or its active ingredients) has been published by government drug authorities in regions outside of the United States.


Q: How long does Calcivita stay in the system after the last use?

A: Pharmacokinetic studies examining the Vitamin D component of Calcivita (Cholecalciferol and its analogues) provide context for how long it stays in the body. These studies suggest that the rate at which the active agents are eliminated from the bloodstream can be a slow process, with a terminal half-life that can range from several hours to over a day.


Q: Does Calcivita lose its effectiveness over time?

A: Official literature does not suggest that the product loses effectiveness or that the body builds tolerance to it while being taken. However, clinical studies have noted that continued effects depend on consistent intake, given that the positive effects on bone mineral density achieved through supplementation are typically lost within a couple of years if the product is discontinued.


Q: Do studies suggest Calcivita has different effects on men versus women?

A: Research that examines the active components of Calcivita has explored differences between biological sexes. These studies indicate that the effects may be partially gender-specific, showing that Vitamin D levels might have a stronger association with bone health in males, while calcium intake may be more influential in females.


Q: How is Calcivita processed by the liver or kidneys?

A: Regulatory documentation notes that certain medications, like Phenytoin, can reduce the effectiveness of Vitamin D3 through increased metabolic clearance. Pharmacokinetic studies of the Vitamin D component confirm that the active substance is processed and eliminated from the body via metabolic pathways that involve both the liver and the kidneys.


Q: Does Calcivita come in different strengths or formulations?

A: Official product information confirms that Calcivita is manufactured in multiple dosage forms. The documentation specifically mentions the availability of soft gelatin capsules or tablets, and also notes the existence of a separate, typically higher-strength 'Forte formulation'.

Advertisements

How should Calcivita be stored and disposed of?

Storage Conditions and Environmental Protection

Official regulatory labeling dictates specific storage conditions to maintain the stability of Calcivita. Calcivita Capsules must be stored below 25 C, while the Forte formulation requires storage below 30 C.

All formulations must be stored in a dry place and protected from direct sunlight to prevent degradation of the active ingredients. The product has an officially stated shelf life of 24 months when stored according to these conditions.

Packaging and Disposal

It is a mandatory regulatory requirement to keep Calcivita out of the sight and reach of children for safety purposes. The product should be stored in its original, tightly closed packaging.

Regarding disposal, official documentation states that there are no special requirements for discarding unused or expired Calcivita product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Calcivita found in:

A-Z Index: